Pages that link to "Q42767460"

The following pages link to P.vincent Jenkins (Q42767460):

Displaying 45 items.

• Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition (Q33419829) (← links)
• Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay (Q34113799) (← links)
• Elevated factor VIII levels and risk of venous thrombosis. (Q34270700) (← links)
• Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation. (Q34304145) (← links)
• Clinical utility gene card for: von Willebrand disease (Q34873778) (← links)
• Clinical utility gene card for: haemophilia A. (Q35406119) (← links)
• Clinical utility gene card for: haemophilia B. (Q35899385) (← links)
• ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? (Q36604393) (← links)
• Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of Factor VIIIa. (Q42533684) (← links)
• Platelet factor 4 impairs the anticoagulant activity of activated protein C. (Q43667908) (← links)
• Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex (Q44045917) (← links)
• Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase (Q44861371) (← links)
• The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia (Q45211606) (← links)
• Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy (Q45856911) (← links)
• Experience of immune tolerance in a carrier of severe haemophilia A with inhibitor development post-surgery. (Q45866428) (← links)
• Inversion mutation analysis in hemophilia a by restriction enzyme analysis and southern blotting (Q45867545) (← links)
• Screening for Candidate Mutations Causing von Willebrand's Disease (vWD). (Q45867553) (← links)
• Multiplex PCR for Detection of the Prothrombin 3'-UTR (G20210A) Polymorphism and the Factor V Leiden Mutation (Q45867573) (← links)
• Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). (Q45868068) (← links)
• Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. (Q45868290) (← links)
• Intron 22 inversions and haemophilia (Q45870538) (← links)
• Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling. (Q45870755) (← links)
• Value of DNA analysis with multiple DNA probes for the detection of hemophilia A carriers. (Q45872704) (← links)
• A recurrent F8 mutation in Irish haemophilia A patients: evidence for a founder effect (Q45874245) (← links)
• Mutation analysis of haemophilia B in the Irish population: increased prevalence caused by founder effect (Q45877553) (← links)
• Age-related factor IX correction in symptomatic female carriers with haemophilia B Leyden. (Q45878029) (← links)
• X-linked moyamoya syndrome associated with severe haemophilia A. (Q45879621) (← links)
• Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII. (Q45884365) (← links)
• Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. (Q45885821) (← links)
• Carrier detection and prenatal diagnosis by intron 22 inversion analysis of the factor VIII gene (Q45886875) (← links)
• Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. (Q46252434) (← links)
• Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes (Q47347418) (← links)
• Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas (Q51541503) (← links)
• Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies. (Q52725146) (← links)
• Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling. (Q54304778) (← links)
• Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation (Q60034598) (← links)
• Concentration-dependent roles for heparin in modifying liopolysaccharide-induced activation of mononuclear cells in whole blood (Q60034601) (← links)
• Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: Influence of glycosylation, proteolysis and gene mutations (Q61784133) (← links)
• Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease (Q61784138) (← links)
• Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors--correlation with absence of Arg506-Gln mutation of factor V gene (Q61784152) (← links)
• Phospholipid membranes drive abdominal aortic aneurysm development through stimulating coagulation factor activity (Q64082405) (← links)
• Will the 'true' factor level make itself known? Measuring factor therapy for treatment of hemophilia in the era of enhanced half-life products (Q64228878) (← links)
• Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline (Q92041367) (← links)
• Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline (Q92143697) (← links)
• The SARS-CoV2 envelope differs from host cells, exposes procoagulant lipids, and is disrupted in vivo by oral rinses (Q112794283) (← links)